Clinical Trial Update: Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: YM BioSciences | Conditions: Recurrent Diffuse Pontine Gliomas | Phase 2 | Status: COMPLETED